Your session is about to expire
β Back to Search
Observational for Sarcoma
N/A
Recruiting
Led By Hector R. Villarraga, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Patients followed at Mayo Clinic and treated for sarcoma with doxorubicin as first-line treatment
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months, 6 months, 1 year
Awards & highlights
Summary
This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check βYesβ for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 3 months, 6 months, 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months, 6 months, 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in myocardial function - 2D-STE
Changes in myocardial function - 2D-STE vs 2D-LVEF and 3D-LVEF
Changes in myocardial function - 2D-STE vs 3D-STE
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: ObservationalExperimental Treatment1 Intervention
Patients receive anthracycline once a day or split between 2-3 days per SOC. Patients undergo 2D-STE throughout the study and have their medical records reviewed on study.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,298 Previous Clinical Trials
3,958,045 Total Patients Enrolled
19 Trials studying Sarcoma
1,845 Patients Enrolled for Sarcoma
Hector R. Villarraga, M.D.Principal InvestigatorMayo Clinic in Rochester
Share this study with friends
Copy Link
Messenger